Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dopamine + metaraminol is a combination of two sympathomimetic agents used to manage acute hypotension, particularly in critical care and perioperative settings. Dopamine acts as a catecholamine neurotransmitter and vasopressor, stimulating dopaminergic receptors at low doses, beta-1 adrenergic receptors at moderate doses (increasing cardiac output), and alpha-1 adrenergic receptors at higher doses (causing vasoconstriction). Metaraminol is primarily an alpha-1 adrenergic receptor agonist with some indirect action via norepinephrine release and minor beta-adrenergic effects; it increases peripheral vascular resistance and blood pressure. The combination may be used when rapid hemodynamic support is required, leveraging both direct vasoconstrictive effects (metaraminol) and inotropic/vasopressor actions (dopamine)[1][2][3][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dopamine + metaraminol.